KR930007447A - Oral medicaments for acid labile compounds - Google Patents

Oral medicaments for acid labile compounds Download PDF

Info

Publication number
KR930007447A
KR930007447A KR1019910018270A KR910018270A KR930007447A KR 930007447 A KR930007447 A KR 930007447A KR 1019910018270 A KR1019910018270 A KR 1019910018270A KR 910018270 A KR910018270 A KR 910018270A KR 930007447 A KR930007447 A KR 930007447A
Authority
KR
South Korea
Prior art keywords
water
oral
hydrogen atom
drug
group
Prior art date
Application number
KR1019910018270A
Other languages
Korean (ko)
Inventor
민동선
엄기안
박경아
Original Assignee
이승동
주식회사 선경인더스트리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이승동, 주식회사 선경인더스트리 filed Critical 이승동
Priority to KR1019910018270A priority Critical patent/KR930007447A/en
Publication of KR930007447A publication Critical patent/KR930007447A/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

본 발명은 벤즈이미다졸 유도체를 유효 성분으로 하는 핵에다 수분차단층과 장용피층을 차례로 형성시킨 산불안정 화합물의 경구용 약제에 있어서, 다음일반식(Ⅰ)의 벤즈이미다졸유도체를 유효성분으로 하는 핵에 피복된 수용성 피막층위에 수분흡착층과 수분차단막이 차례로 형성되어 있고, 그 위에 장용 성피막물질이 피복되어 있는 것으로서, 위장관 치료에 효과적인 산불안정 화합물의 경구용 약제이다.The present invention is an oral drug of an acid labile compound in which a nucleus containing a benzimidazole derivative as an active ingredient is formed in order to form a water barrier layer and an enteric coating layer, wherein the benzimidazole derivative of the following general formula (I) is used as an active ingredient. A water adsorption layer and a water barrier film are sequentially formed on the water-soluble coating layer coated on the nucleus, and the enteric coating material is coated thereon, and is an oral drug of an acid labile compound effective for treating the gastrointestinal tract.

여기서, R1은 수소원자, 메톡시, 트리플루오로메틸 또는 테트라플루오로레톡시기이고, R2는 수소원자, 메틸 또는 디메틸아민기이고, R3는 수소원자, 메톡시, 아릴옥시, 프로파길옥시기이고, R4는 수소원자, 메틸기이다.Wherein R 1 is a hydrogen atom, methoxy, trifluoromethyl or tetrafluororeoxy group, R 2 is a hydrogen atom, methyl or dimethylamine group, R 3 is a hydrogen atom, methoxy, aryloxy, propa It is a giloxy group, R <4> is a hydrogen atom and a methyl group.

Description

산불안정 화합물의 경구용 약제Oral medicaments for acid labile compounds

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (11)

벤즈아미다졸 유도체를 유효성분으로 하는 핵에다 수분차단층과 장용피층을 차례로 형성시킨 산불안정 화합물의 경구용 약제에 있어서, 벤즈이미다졸유도체를 유효성분으로 하는 핵에 피복된 수용성피막층위에 수분흡착층과 수분차단막이 차례로 형성되어 있고, 그 위에 장용성피막물질이 피복되어 있는 것을 특징으로 하는 산불안정 화합물의 경구용 약제.An oral drug of an acid labile compound in which a water barrier layer and an enteric coating layer are sequentially formed in a nucleus having a benzimidazole derivative as an active ingredient, wherein the water adsorption layer is placed on a water-soluble coating layer coated on the nucleus having the benzimidazole derivative as an active ingredient. And an aqueous barrier film are formed in this order, and an enteric coating material is coated thereon. 제1항에 있어서, 상불안정 화합물을 다음일반식(Ⅰ)을 갖는 벤즈이미다졸 유도체인 것을 특징으로 하는 경구용 약제.The oral pharmaceutical agent according to claim 1, wherein the phase labile compound is a benzimidazole derivative having the following general formula (I). 여기서, R1은 수소원자, 메톡시, 트리플루오로메틸 또는 테트라플루오로에톡시기이고, R2는 수소원자, 메틸 또는 디메틸아민기이고, R3는 수소원자, 메톡시, 아릴옥시, 프로파기리옥시기이고, R4는 수소원자, 메틸기이다.Wherein R 1 is a hydrogen atom, methoxy, trifluoromethyl or tetrafluoroethoxy group, R 2 is a hydrogen atom, methyl or dimethylamine group, R 3 is a hydrogen atom, methoxy, aryloxy, pro It is a pagirioxy group, R <4> is a hydrogen atom and a methyl group. 제1항에 있어서, 상기 핵은 정제, 구형펠릿, 과립제, 세립제, 캡슐 또는 마이크로 캡슐형태로 이루어진 것을 특징으로 하는 경구용 약제.According to claim 1, wherein the nucleus is an oral medicament, characterized in that it consists of tablets, spherical pellets, granules, granules, capsules or microcapsules. 제1항에 있어서, 상기 수용성피막층은 히드록시프로필셀룰로오스, 히드록시 프로필메틸셀룰로오스 또는 폴리비닐피롤리돈으로 이루어져 있고, 하나 또는 2개 이상의 층으로 이루어져 있는 것을 특징으로 하는 경구용 약제.According to claim 1, wherein the water-soluble coating layer is composed of hydroxypropyl cellulose, hydroxy propyl methyl cellulose or polyvinylpyrrolidone, oral medicament, characterized in that consisting of one or two or more layers. 제1항 또는 제4항에 있어서, 수용성피막층은 전체 약제 무게에 대하여 0.1~30중량%인 것을 특징으로 하는 경구용 약제.The oral drug according to claim 1 or 4, wherein the water-soluble coating layer is 0.1 to 30% by weight based on the total weight of the drug. 제1항에 있어서, 상기 수분흡착층은 경질무수규산, 마그네슘트리실리케이트, 카올린, 벤토나이트, 산화마그네슘, 연산 칼슘 및 탄산마그네슘 중에서 선택된 하나 또는 둘 이상의 혼합물로 이루어져 있으며, 하나 또는 2개 이상의 층으로 이루어져 있는 것을 특징으로 하는 경구용 약제.The method of claim 1, wherein the water adsorption layer is composed of one or two or more selected from hard silicic anhydride, magnesium trisilicate, kaolin, bentonite, magnesium oxide, calcium calcium and magnesium carbonate, and comprises one or two or more layers. Oral pharmaceuticals characterized in that. 제1항 또는 제6항에 있어서, 상기 수분흡착층은 전체 약제 무게에 대하여 1~80중량%인 것을 특징으로 하는 경구용 약제.According to claim 1 or 6, wherein the moisture adsorption layer is an oral drug, characterized in that 1 to 80% by weight based on the total weight of the drug. 제1항에 있어서, 상기 수분차단막 물질은 백납, 경납, 카나우바왁스, 메타크릴산에스테르공중합체, 세탄올, 세탄올지방산에스테르, 쉘락, 히드록시프로필 메틸셀룰로오스, 에틸셀룰로오스, 폴리비닐아세테이트 및 셀룰로오스아세테이트 중에서 선택된 하나 또는 둘 이상의 혼합물로 이루어진 것을 특징으로 하는 경구용 약제.The method of claim 1, wherein the moisture barrier membrane material is lead lead, braze wax, carnauba wax, methacrylic acid ester copolymer, cetanol, cetanol fatty acid ester, shellac, hydroxypropyl methyl cellulose, ethyl cellulose, polyvinylacetate and cellulose Oral medicament, characterized in that consisting of one or more mixtures selected from acetate. 제1항 또는 제8항에 있어서, 상기 수분차단막을 전체 약제 무게에 대하여 0.1~30중량%인 것을 특징으로 하는 경구용 약제.The oral medicine according to claim 1 or 8, wherein the moisture barrier membrane is 0.1 to 30% by weight based on the total weight of the medicine. 제1항에 있어서, 상기 장용성피막물질은 히드록시프로필메틸셀룰로오스프탈레이트, 셀룰로오스아세테이트프탈레이트, 폴리비닐아세테이트프탈레이트 또는 메타크릴산-메타크릴산메틸아세트르 공중합체로 이루어진 것을 특징으로 하는 경구용 약제.The oral pharmaceutical agent according to claim 1, wherein the enteric coating material is made of hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, polyvinylacetate phthalate or methacrylic acid-methyl methacrylate copolymer. 유효성분으로서의 산불안정 화합물을 함유하는 핵을 중심으로 그 위에 수용성피막층과 수분흡착층, 수분차단막 및 장용성피막물질이 차례로 피복되어 경구투여할 수 있도록 된 위장관치료용 약제.A drug for the treatment of gastrointestinal tracts, which is coated with a water-soluble coating layer, a water adsorption layer, a water barrier film, and an enteric coating material, in order, on a nucleus containing an acid labile compound as an active ingredient, in order to be orally administered. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019910018270A 1991-10-17 1991-10-17 Oral medicaments for acid labile compounds KR930007447A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019910018270A KR930007447A (en) 1991-10-17 1991-10-17 Oral medicaments for acid labile compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019910018270A KR930007447A (en) 1991-10-17 1991-10-17 Oral medicaments for acid labile compounds

Publications (1)

Publication Number Publication Date
KR930007447A true KR930007447A (en) 1993-05-20

Family

ID=67348465

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910018270A KR930007447A (en) 1991-10-17 1991-10-17 Oral medicaments for acid labile compounds

Country Status (1)

Country Link
KR (1) KR930007447A (en)

Similar Documents

Publication Publication Date Title
TW495363B (en) Tramadol multiple unit formulations
ES2226886T3 (en) FORM OF ADMINISTRATION OF DELAYED ACTION CONTAINING SQUARINATE OF TRAMADOL.
FI122017B (en) Multi-unit, tableted dosage form
JP4183746B2 (en) Novel stable galenic preparation containing acid labile benzimidazole and method for producing the same
JP3198337B2 (en) Novel composition containing acid-labile benzimidazole and method for producing the same
ES2205243T3 (en) STABLE MEDICINAL FORM WITH DERIVATIVES OF DENCIMIDAZOL AS AN ACTIVE SUBSTANCE, INTENDED FOR ADMINISTRATION BY ORAL, AND PROCEDURE FOR YOUR PREPARATION.
FI93422C (en) A process for preparing an oral preparation containing an acid-stable benzimidazole derivative
ES2303238T3 (en) GRANULATED SLOW RELEASE PREPARATION CONTAINING A DRUG WITH PARTICULATE BASED AMINA STRUCTURE WITH A COATING COAT AND THE CORRESPONDING PRODUCTION METHOD.
KR890006242A (en) Controlled Release of New Tetracycline Compounds
PT97370B (en) PROCESS FOR THE PREPARATION OF A CONTROLLED LIBERATION FORMULA IN THE FORM OF A PLURALITY OF MULTIDOSE UNITS
BR9914977B1 (en) Modified release multiparticulate composition
KR870009718A (en) Pharmaceuticals with oral acid labile substances
KR910011257A (en) Solid pharmaceutical compositions containing cimetidine and methods for preparing the same
BRPI0711606A2 (en) delayed release duloxetine hydrochloride formulations
KR870009717A (en) New Oral Medicines
WO2001054671A1 (en) Sustained-release preparation and process for producing the same
BRPI0614870A2 (en) pharmaceutical compositions
JP2001199878A (en) Oral solid preparation including acid-sensitive benzimidazole having modified releasing properties
JPS63139128A (en) L-dopa-containing composition, coating method and therapy for parkinsonism
HRP20020119A2 (en) Taste masked pharmaceutical liquid formulations
EP0211991B1 (en) Substained release tablets and method for preparation thereof
BRPI0615014A2 (en) solid pharmaceutical composition comprising 1- (4-chloroanilino) -4- (4-pyridylmethyl) phthalazine and a ph modifier and use thereof
RU2006118689A (en) CONTAINING PHARMACEUTICAL AGENT COMPOSITION COATED
JPH06279274A (en) Suspension controlled release type medicine composition
HUT78132A (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL